pdufa.bio
HomeDecisions › AMRX 2026-06-04

AMRX FDA decision — Jun 4, 2026

✓ APPROVED

Amneal Pharmaceuticals Inc. — Romidepsin injection solution, 27.5 mg/5.5 m · Cutaneous T-cell lymphoma.

Run-up into the decision (T-120 → T+5)

PDUFA 6/4/26$15.19$11.8112/18/25
Daily close, T-120 (12/18/25) through T+5. Run-up high $15.19 on 2/19/26, low $11.81 on 5/20/26 (T-120 to T-1). FDA decision 6/4/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-04
OutcomeApproved
Drug / candidateRomidepsin injection solution, 27.5 mg/5.5 m
CompanyAmneal Pharmaceuticals Inc.
120-day run-up (T-120→T-1)+5.4%